Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis
Rojo A. Ratsimandresy, Emma Doran, Hart S. Dengler, Sarah Emily Headland, Christopher J. Wedeles, Riccardo Guidi, Daqi Xu, Jiatong Liu, Yongchang Shi, Jianyong Wang, Salil Uttarwar, Alexander R. Abbas, Tianhe Sun, Daryle J. DePianto, Katrina B. Morshead, , Mark S. Wilson
This study shows that blocking OSM and IL-6 reduces fibrosis and inflammation in pulmonary fibrosis by targeting their shared receptor and distinct pathways.
bioRxiv · Jan 13, 2026 · PreprintImmunology